This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.
Age > 21 years
New pathologically confirmed diagnosis of WHO grade IV malignant glioma
KPS > 60
Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol
History of previous malignancy other than non-melanoma skin cancer in the previous 5 years
History of iron metabolic disorder such as hemochromatosis
Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices
John M. Buatti
Lead sponsor
University of Iowa
Sponsor institution